Allinaire is developing humanized anti-endothelial monocyte activating polypeptide II (EMAP II) monoclonal antibodies, which are currently being progressed as a potential disease-modifying treatment for PAH. Allinaire was founded in 2016 by BioMotiv (www.biomotiv.com; now managed by Advent Life Sciences, www.adventls.com), with the licensed technology from Indiana University.
EMAP II is a non-classical cytokine which impacts apoptosis, cell injury, endothelial cell function and inflammation. Based on the pioneering work by the scientific founders, Matthias Clauss, PhD and Irina Petrache, MD, and their colleagues at Indiana University and National Jewish Health, Allinaire Therapeutics and their network of preclinical and clinical scientists, have demonstrated a pivotal pathogenic role of EMAP II in cardiopulmonary diseases, including pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and viral-induced acute lung injury.
Our Team
Featured
Key Scientific Advisors and Collaborators
Sebastien Bonnet, PhD, FAHA
Professor of Medicine
Pulmonary Hypertension Research Group
University of Laval
Steeve Provencher, MD, MSc, FRCPC
Professor of Medicine
Pulmonologist
Pulmonary Hypertension Research Group
University of Laval
Tim Lahm, MD, ATSF
Professor, Division of Pulmonary, Critical Care & Sleep Medicine
Pulmonologist
National Jewish Health
David Knight, PhD
Antibody Development
Former VP BioPharmaceutical Research, Centocor/J&J
Steve Holmes, PhD
Antibody Development
CEO and Founder at Capella BioScience, a Centessa company
Former Senior Director, GSK
Board
Satish Jindal, PhD
Chairman and Manager of the Board
Partner, Advent Life Sciences
Arthur Bertelsen, PhD
Business Advisor and Member of the Board
Former VP, Research Collaborations, BMS
Schering-Plough Research Institute
Brian Stemme
Member of the Board
Senior Vice President of Engagement for BioCrossroads